Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.

Nominally significant improvement ( P < 0.05) in the HAMD‐17 total score was observed in the zuranolone 20‐ and 30‐mg groups when compared with the placebo group during the early treatment period on Days 3 and 8 (Table 2 and Fig. 3 ).

also in 7,732 other papers